Alzheimer Dementia: Effects of intensive blood pressure reduction on plasma Aβ, neurofilament light chain and total tau in dementia in the SPRINT trial

It has become a consensus that lowering blood pressure can reduce the risk of cardiovascular disease, but whether lower blood pressure is better, and what should be the ideal blood pressure lowering target? The large-scale SPRINT clinical trial conducted in the United States in 2015 demonstrated the benefits of aggressive antihypertensive strategies for the first time

At the same time, lowering blood pressure reduces the risk of cognitive impairment and leukoencephalopathy progression, but it is unclear whether hypertension control also affects plasma biomarkers associated with Alzheimer's disease (AD) and non-disease-specific neurodegeneration thing

SPRINT trial investigators investigated the effect of intensive (<120mmHg) versus standard (<140mmHg) blood pressure control on longitudinal changes in plasma amyloid beta (Aβ)40 and Aβ42, total tau and neurofilament light chain (NfL) in participants from contraction A subgroup of the stress intervention trial (N = 517)

Results showed little between-group differences in Aβ40, Aβ42, Aβ42/Aβ40, or total tau at 3.

In conclusion, intensive blood pressure therapy was associated with changes in NfL, and changes in NfL were associated with changes in renal function associated with intensive therapy

references:

Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT)